- The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc's ELOX ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations.
- ELX-02 is currently in Phase 2 clinical trials. It expects to present data from the first four treatment arms in the fourth quarter of 2021.
- Related Content: Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021.
- ELX-02 has previously been granted orphan drug designation by the FDA and orphan medicinal product designation by the European Medicines Agency.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ELOX stock is up 12.60% at $1.57 during the market session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
